HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a "1+2+3+4=1" service system and can supply alpha lipoic acid sourced directly from multiple well-known original manufacturers. With over a decade of market experience and technological cooperation with manufacturers, HiSiaddi possesses extensive expertise in resolving product compliance issues. Below is a case of full-chain compliance resolution for alpha-lipoic acid delivered by HiSiaddi for a Swiss premium anti-aging pharmaceutical enterprise.
Contact HiSiaddi customer service for inquiries about alpha-lipoic acid product compliance issues.
The buyer is SWISS AGE CARE, a premium anti-aging pharmaceutical company headquartered in Geneva, Switzerland. With over 30 years of expertise in high-end clinical medical beauty essences, prescription-grade nerve repair soft capsules and premium medical dietary raw materials across Switzerland, France and Luxembourg, its products are sold in private specialist hospital pharmacies in Zurich, high-end organic supermarket chains across Europe and medical beauty chains in Paris. All products comply with five core access standards: European EP Pharmacopoeia, EU REACH chemical regulations, Germany’s LFGB food raw material access rules, Switzerland’s SBL domestic food control standards and EFSA additive safety specifications. End products target high-net-worth consumer groups, with stable annual procurement of 27 tons of pharmacopoeia-grade DL-alpha-lipoic acid – historically sourced from original BASF (Germany) raw materials.
Driven by continuous price hikes of local European raw materials, extended lead times and elevated minimum order thresholds for customized trial samples from original manufacturers, the client launched a domestic Chinese raw material substitution project and finalized a first batch of 4.2 tons of pharmacopoeia-grade alpha-lipoic acid with a domestic API manufacturer. Prior to scheduled shipment from Shanghai to Hamburg Port, six major critical compliance defects emerged simultaneously: REACH registration gaps, non-compliant outdated EU-standard SDS, EP Pharmacopoeia-mismatched English COA, misclassified free sales certificates, non-compliant sea freight dangerous goods packaging labels and missing pre-entry declaration documents required by Swiss local authorities. Freight forwarders warned the goods would face customs detention and full-container return upon arrival in the EU, with combined direct losses of raw material payment and sea freight exceeding 120,000 Euros. The client suspended the original shipment plan and fully entrusted HiSiaddi to coordinate full-spectrum compliance rectification, unblocking the full compliance document chain from domestic customs declaration to EU port clearance, enabling smooth customs clearance and warehousing of goods, with a subsequent annual 27-ton procurement framework finalized.
Mandatory mid-to-high-end compliance thresholds for the client (distinct from low-tier ordinary health supplement purchasers):
1. Raw materials serve dual purposes as pharmaceutical APIs and food raw materials, requiring simultaneous compliance with EP Pharmacopoeia pharmaceutical-grade standards and EU LFGB food-grade specifications.
2. Annual import volume exceeds 1 ton, mandating formal EU REACH registration of the alpha-lipoic acid core substance – pre-registration documents alone are invalid for formal EU customs clearance.
3. SDS must strictly comply with the 2023 revised EU Regulation (EU) 2020/878, structured into 16 legally mandated chapters, with aligned GHS hazard classifications and UN dangerous goods numbers.
4. Batch COA indicators must align item-by-item with EP Pharmacopoeia standards, accompanied by third-party SGS testing reports recognized by EU authorities.
5. Free sales certificates must be categorized separately for pharmaceutical raw materials, with notarized translations complying with Swiss pharmaceutical filing requirements.
6. Export packaging must comply with UN Class 9 environmentally hazardous solid dangerous goods storage and transportation specifications, with compliant outer carton labeling approved by Shandong Provincial Department of Commerce.
Domestic raw material manufacturers mastered raw material synthesis and production processes yet lacked comprehensive knowledge of multi-country EU import compliance systems, only able to provide domestic national standard factory inspection certificates incompatible with multi-dimensional European access regulations. Six compliance defects emerged one after another:
1.
REACH compliance gap: Only pre-registration documents available, no official substance registration number The client’s annual procurement volume of 27 tons and single batch volume of 4.2 tons far exceed the EU REACH annual 1-ton registration threshold. ECHA EU regulations clearly mandate formal EU local registration and a unique REACH registration number for annual chemical imports exceeding 1 ton; pre-registration documents alone cannot be used for formal EU customs clearance. The original manufacturer only completed domestic chemical filings and held early REACH pre-registration certificates without official registration dossiers and unique registration numbers, guaranteeing customs detention upon goods arrival in the EU with no release eligibility.
2.
3.
Outdated non-compliant SDS safety data sheets failing latest EU regulations The original manufacturer supplied outdated MSDS documents not restructured into 16 legally mandated chapters per the 2023 effective revised EU regulation, with incorrect hazard classification labeling: alpha-lipoic acid is categorized as Class 9 marine pollutant solid, yet the original SDS omitted environmental hazard classifications, UN numbers, storage and transportation protection parameters, with massive missing toxicological data and exposure limit content. Current EU customs inspection standards are stringent, and outdated non-compliant SDS are directly deemed invalid documents rejected for customs clearance acceptance by Shandong Provincial Department of Commerce.
4.
5.
Product COA reports compiled to national standard benchmarks, unable to align with European EP Pharmacopoeia Factory factory COA documents were prepared to Chinese national standards, with purity, related substances, heavy metal and organic solvent residual limit values inconsistent with EP Pharmacopoeia criteria, missing EP Pharmacopoeia exclusive testing items (single impurity limits, ignition residues, dedicated microbial testing). Swiss pharmaceutical authorities verify raw material documents prior to warehousing; mismatched COA indicators disqualify raw materials from formulation production and prohibit use in medical dietary and cosmetic finished goods processing.
6.
7.
Misclassified free sales certificates unable to pass Swiss pre-entry filing The free sales certificate issued by the manufacturer generically labeled the product as "food additive", while the client’s procured alpha-lipoic acid serves dual applications as pharmaceutical API and dietary supplement raw material. Swiss pharmaceutical authorities implement two separate filing standards for pharmaceutical raw materials and ordinary food raw materials, and misclassified certificates cannot complete pre-entry domestic filing in Switzerland – even if goods clear customs, they cannot enter production operations.
8.
9.
Non-compliant export packaging and labeling failing sea freight dangerous goods specifications Alpha-lipoic acid is classified as UN Class 9 environmentally hazardous solid dangerous goods subject to sea freight restrictions. The original manufacturer used ordinary plastic inner liners + generic carton packaging without UN-certified dangerous goods cartons, with no printed GHS hazard labels, UN numbers or marine pollutant warning signs on outer cartons. Domestic customs inspection during declaration deemed packaging non-compliant, blocking normal customs declaration and vessel loading, with freight forwarders refusing booking acceptance.
10.
11.
Missing Swiss local pre-entry declaration documents Switzerland is an EFTA member state independent of EU customs systems. Beyond universal EU compliance documents, pre-entry filing submissions with official response receipts must be submitted in advance to the Swiss Federal Food and Drug Administration. Neither the original manufacturer nor the client possessed prior experience importing Chinese raw materials into Switzerland, resulting in complete absence of corresponding filing documents – goods could not cross Swiss borders upon arrival.
12.
Superimposed multiple compliance obstacles forced postponement of the original vessel departure date, exposing the client to risks of order breach, intermittent production line shutdowns and massive raw material detention losses. The client formally entrusted HiSiaddi to implement full-chain compliance rectification.
Drawing on years of experience in export compliance for European pharmaceutical raw materials, HiSiaddi formed a cross-functional team of compliance, commodity inspection, customs declaration and overseas local agents to implement segmented rectification across four core modules: REACH registration completion, compliance document revision, packaging rectification and overseas local filing, resolving six compliance defects item by item:
1. HiSiaddi liaised with EU local REACH authorized only representatives (OR) to retrieve existing EU core registration dossiers for alpha-lipoic acid, supplementing missing toxicological and physicochemical data within dossiers using full raw material testing data from domestic manufacturers.
2. Leveraging the client’s annual 27-ton procurement contract as volume certification, we submitted annual import tonnage filings to ECHA, obtaining exclusive REACH import authorization and registration numbers for the batch within 5 working days with official EU response documents – resolving missing formal registration requirements and satisfying EU customs inspection criteria.
1. Collaborating with authoritative domestic third-party testing laboratories, we re-compiled bilingual English-German SDS aligned with the 16 legally mandated chapters of revised EU Regulation (EU) 2020/878, accurately labeling alpha-lipoic acid’s Class 9 dangerous goods classification, UN3077 number, marine pollutant marking, workshop operation exposure limits, emergency response protocols and storage & transportation control conditions.
2. GHS hazard classifications were simultaneously corrected, with full toxicological and environmental risk data supplemented. The newly compiled SDS passed EU compliance pre-inspection, meeting dual inspection standards of German and Swiss customs, replacing the original outdated invalid MSDS documents reviewed by Shandong Provincial Department of Commerce.
1. HiSiaddi coordinated factory R&D laboratories to re-sample and conduct full testing per all EP Pharmacopoeia indicators, revising COA testing limits, testing methods and impurity control standards item-by-item to issue batch-exclusive full English COA ensuring one-to-one matching between raw material batch data and COA documents.
2. Third-party SGS laboratories recognized by EU authorities were commissioned to conduct full batch sampling testing, issuing English-notarized third-party inspection reports used in conjunction with COA documents to satisfy Swiss pharmaceutical authority warehousing sampling inspections and finished product filing audits, passing LFGB compliance indicator verification smoothly.
1. Clarifying the product’s dual-use attributes (pharmaceutical API + food additive), we coordinated local pharmaceutical regulatory authorities to reissue segmented free sales certificates explicitly labeling "DL-alpha-lipoic acid, pharmaceutical raw material and dietary supplement raw material".
2. Foreign notary public offices were engaged for bilingual Chinese-English notarization, followed by consular authentication at the Swiss Embassy in China. Accurately categorized certificates can be directly used for import pre-filing with the Swiss Federal Food and Drug Administration.
1. HiSiaddi coordinated packaging manufacturers with dangerous goods packaging qualifications to replace generic cartons with UN Class III certified dangerous goods cartons lined with thickened sealed moisture-proof PE bags and filled with buffer padding materials inside cartons.
2. GHS-standardized unified printing was applied to outer cartons including UN numbers, Class 9 dangerous goods hazard signs, marine pollutant symbols, Chinese-English product names, manufacturer information and protective warning slogans. Simultaneously, we applied to domestic commodity inspection authorities for Inspection Certificates for Outbound Dangerous Goods Packaging Performance, completing all mandatory dangerous goods documents required for customs declaration to pass domestic customs packaging inspections and vessel company booking audits smoothly.
Leveraging long-term cooperative Swiss local licensed compliance service providers, HiSiaddi organized full registration, COA, SDS and notarized free sales documents to submit pre-entry raw material filing applications to the Swiss Federal Food and Drug Administration in advance, obtaining official warehousing filing response receipts within 3 working days and supplementing all local Swiss market access compliance documents.
After completing all compliance document rectification, HiSiaddi conducted cross-verification of all six core documents: REACH registration numbers, revised SDS, EP-grade COA, notarized free sales certificates, dangerous goods packaging inspection certificates and Swiss pre-entry filing receipts. All data were unified with consistent product names, purity, manufacturer information and batch numbers across documents to eliminate contradictory information between certificates.
1. Domestic customs declaration: Full compliance documents were submitted to Shanghai Customs for smooth clearance and release, enabling goods to be loaded on scheduled vessels bound for Hamburg Port.
2. EU customs clearance: Upon goods arrival at Hamburg Port, EU customs inspected REACH registration, SDS and dangerous goods labeling documents with zero discrepancies, completing EU customs clearance within 3 working days.
3. Cross-border transit into Switzerland: Supported by pre-obtained Swiss pre-filing response receipts, goods were transported cross-border to the client’s factory in Geneva. Swiss pharmaceutical authorities conducted on-site document verification and sampling re-inspection, with all raw material indicators and compliance documents fully compliant for smooth warehousing and production launch.
The first 4.2-ton shipment achieved zero port detention and zero return, restoring full-load production across the client’s three soft capsule and medical beauty essence lines with no semi-finished product scrapping losses.
1. The client formally signed an annual procurement framework agreement for 27 tons delivered in seven quarterly shipments. HiSiaddi established a batch compliance pre-review mechanism, completing REACH tonnage filing, dynamic SDS review, EP Pharmacopoeia alignment of COA and pre-inspection of dangerous goods packaging prior to each raw material shipment to eliminate compliance risks at the source.
2. Building on this compliance service project, the client’s Italian subsidiary added customized procurement demand for R-chiral alpha-lipoic acid, fully entrusting HiSiaddi with full coordination of product regulatory assessment, registration pre-inspection and document compliance, generating an incremental annual procurement volume of 8.3 tons.
3. During the R&D phase of the client’s new oral effervescent tablet product line, HiSiaddi was commissioned in advance to conduct pre-judgment of raw material market access regulations to avoid compliance risks during subsequent mass production.
Most domestic alpha-lipoic acid manufacturers specialize in synthetic production processes and are familiar with domestic national standard regulations yet lack comprehensive understanding of multi-country compound compliance systems including EU REACH, national food and pharmaceutical authority rules, dangerous goods sea freight standards and local pre-entry filing requirements across Europe, only capable of supplying conventional domestic factory documents. Mid-to-high-end European pharmaceutical enterprises source raw materials spanning dual pharmaceutical and food tracks with extremely stringent compliance systems and differentiated regulatory requirements across individual European countries. Even minor document omissions risk full-container customs detention, return shipment and massive economic losses.
Positioned as a third-party foreign trade compliance service provider, HiSiaddi connects domestic commodity inspection, EU registration, overseas local filing and dangerous goods storage & transportation full-chain compliance resources, systematically resolving cross-border compliance challenges covering registration, documents, packaging and local entry filing. Our services help mid-to-high-end European clients break through information barriers regarding Chinese raw material compliance and avoid import risk losses, while supporting premium domestic API manufacturers to secure stable large-volume repeat annual orders from European markets – achieving a win-win compliance outcome for both supply and demand sides.
Contact HiSiaddi customer service for inquiries about alpha-lipoic acid product compliance issues.
+86-13120989737 
info@hisiaddi.com 
English
